X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

RB invests $25 mn to set up new Reckitt Global Hygiene Institute

Content Team by Content Team
20th July 2020
in Drug Development, Press Statements
RB invests $25 mn to set up new Reckitt Global Hygiene Institute

RB is investing $25 million to set up the Reckitt Global Hygiene Institute (RGHI) which is a research and innovation hub that will bridge epidemiology, public health, and behavioural insights to generate practical, high-quality scientific research that leads to enduring behaviour change.

“The COVID-19 pandemic has pushed public health to the top of the global agenda. At RB, we see the need for a new paradigm that brings together the highest quality scientific based evidence and informed public health recommendations to generate large-scale behaviour change for a cleaner, healthier world,” said Laxman Narasimhan, CEO, RB.

“Today we’re announcing our commitment to convene a group of multi-disciplinary experts who, like us, believe real change on a global scale is within reach if we translate science-based evidence and consumer behavioural insights into sustainable hygienic practices that can be adopted globally. This ambitious goal is the result of our belief that the highest quality hygiene is a right and not a privilege,” he added.

The company’s commitment to global hygiene research and education includes the formation of an Expert Panel with to guide these research efforts at leading academic institutions around the world.

The creation of a Global Hygiene Institute with physical infrastructure, with a governing board will be supported by full-time staff, ongoing research, and education programming driven by expert researchers and educators.

Through the establishment of a fellowship program with leading universities, RGHI will generate practical, informed public health research and recommendations that champion global hygiene as the foundation of health. The Governing Board will determine specific areas for research and will work with the Expert Panel to award the fellowships to promising early career academics, who will become Reckitt Fellows. In addition to the fellowships, the Institute will award grants to institutions for open, collaborative, cross-functional research. The Expert Panel will further define the parameters of these awards.

The Governing Board and Expert Panel include Professor Peter Piot, Director of the London School of Hygiene & Tropical Medicine, Dame Sally Davies, Master of Trinity College, Cambridge, Professor Feng Cheng, Research Center for Public Health, Tsinghua University School of Medicine, Tsinghua, Dr. Randeep Guleria, Director, All India Institute of Medical Sciences (AIIMS), Professor Dr. Albert Ko, Department Chair and Professor of Epidemiology, Yale School of Medicine and Professor Teo Yik Ying, Dean, Saw Swee Hock School of Public Health, National University of Singapore.

Previous Post

Heron Therapeutics initiates phase 2 GUARDS-1 study of Cinvanti to treat COVID-19

Next Post

IDEAYA Biosciences meets clinical protocol criteria for cohort expansion in skin melanoma for phase 2 GNAQ/11 basket trial

Related Posts

Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Next in Pharma 2025 Innovations
Articles

Next in Pharma 2025: Innovations Shaping the Future

28th May 2025
Insights

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

27th May 2025
Next Post
Regeneron, Intellia to develop CRISPR/Cas9-based treatments

IDEAYA Biosciences meets clinical protocol criteria for cohort expansion in skin melanoma for phase 2 GNAQ/11 basket trial

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In